CAS: 58551-69-2; 2-Amino-2-(Hydroxymethyl)Propane-1,3-Diol (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((S,E)-3-Hydroxy-3-Methyloct-1-En-1-yl)Cyclopentyl)Hept-5-Enoic Acid

γ-Lactone Of 2β-(3-Oxo-Trans-1-octenyl)-3α-Hydroxy-5α-Hydroxy-1α-Cyclopentylacetic Acid置于咪唑,Potassium Tert-Butylate,四丁基氟化铵,水,二异丁基氢化铝,Lithium Hydroxide体系中,用 四氢呋喃,甲醇,二氯甲烷,N,N-二甲基甲酰胺 作为反应溶剂,化学反应 22.67H,反应生成 卡前列素氨基丁三醇
参考文献:一种前列腺素类似物的制备方法
标题:一种前列腺素类似物的制备方法
摘要:本发明公开了一种前列腺素类似物的制备方法,所述前列腺素类似物为如式9所示化合物,具体合成路线如下:本发明所用试剂和原料均市售可得,该制备方法反应条件温和,操作简便,能耗和成本低,产率较高,适合工业化生产.

专利信息

专利号:US-7772278-B2
优先权日:1999-03-01
标 题:Nitrosated and nitrosylated prostaglandins, compositions and methods of use
发明人：GARVEY DAVID S; GASTON RICKY D; LETTS L GORDON; DE TEJADA INIGO SAENZ; TAM SANG WILLIAM; WORCEL MANUEL
权利人:NITROMED INC
摘要:The invention describes novel nitrosated and/or nitrosylated prostaglandins, and novel compositions comprising at least one nitrosated and/or nitrosylated prostaglandin, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The invention also provides novel compositions comprising at least one prostaglandin and at least one S-nitrosothiol compound, and, optionally, at least one vasoactive agent. The prostaglandin is preferably a prostaglandin E 1 compound, more preferably alprostadil, and the S-nitrosothiol compound is preferably S-nitrosoglutathione. The invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cerebrovascular disorders, cardiovascular disorders, benign prostatic hyperplasia (BPH), glaucoma, peptic ulcers or for inducing abortions.

专利号:WO-0054773-A1
优先权日:1999-03-12
标题:Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
发明人：GARVEY DAVID S
权利人:NITROMED INC; GARVEY DAVID S
摘要:The present invention is directed to novel compositions comprising at least one dopamine agonist in combination with at least one nitric oxide donor (i.e. compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or are substrates for nitric oxide synthase). The novel compositions may optionally comprise at least one therapeutic agent, such as, a vasoactive agent, an antimetic agent, and mixtures thereof. The dopamine agonist is preferably apomorphine. The present invention is also directed to methods for treating and/or preventing sexual dysfunctions and/or enhancing sexual responses in patients. In other embodiments, the present invention is directed to methods treating or preventing neurodegenerative diseases, mitochondrial diseases, spinal cord injury, central or psychostimulant addiction, senile dementia, circulatory disorders, cardiovascular disorders, hyperprolactinaemia or myopia. The compounds and/or compositions of the present invention can also be provided in the form of a pharmaceutical kit.

专利号:US-6030613-A
优先权日:1995-01-17
标题:Receptor specific transepithelial transport of therapeutics
发明人：BLUMBERG RICHARD S; SIMISTER NEIL E; LENCER WAYNE I
权利人:BRIGHAM & WOMENS HOSPITAL; UNIV BRANDEIS
摘要:The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the invention relates to methods and compositions for the delivery of therapeutics conjugated to a FcRn binding partner to intestinal epithelium, mucosal epithelium and epithelium of the lung. The present invention further relates to the synthesis, preparation and use of the FcRn binding partner conjugates as, or in, pharmaceutical compositions for oral systemic delivery of drugs and vaccines.

专利号:US-7547436-B2
优先权日:1995-01-17
标 题:Receptor specific transepithelial transport of therapeutics
发明人：BLUMBERG RICHARD S; LENCER WAYNE I; SIMISTER NEIL E
权利人:BRIGHAM & WOMENS HOSPITAL; UNIV BRANDEIS
摘要:The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the invention relates to methods and compositions for the delivery of therapeutics conjugated to a FcRn binding partner to intestinal epithelium, mucosal epithelium and epithelium of the lung. The present invention further relates to the synthesis, preparation and use of the FcRn binding partner conjugates as, or in, pharmaceutical compositions for oral systemic delivery of drugs and vaccines.

专利号:US-2007148246-A1
优先权日:2005-08-11
标题:Nucleic Acid-Based Matrixes
发明人：LUO DAN; LI YOUGEN
权利人:LUO DAN; LI YOUGEN
摘要:Various nucleic acid-based matrixes are provided, comprising nucleic acid monomers as building blocks, as well as nucleic acids encoding proteins, so as to produce novel biomaterials. Methods of utilizing such biomaterials include delivery of biologically active agents, cell and tissue culture, and cell-free protein synthesis.

专利号:US-8486621-B2
优先权日:2005-08-11
标题 :Nucleic acid-based matrixes
发明人：LUO DAN; UM SOONG HO
权利人:LUO DAN; UM SOONG HO; CORNELL RES FOUNDATION INC
摘要:Various nucleic acid-based matrixes are provided, comprising nucleic acid monomers as building blocks, as well as nucleic acids encoding proteins, so as to produce novel biomaterials. Methods of utilizing such biomaterials include cell-free protein synthesis.